Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Licensed medicineStub

Semaglutide

GLP-1 receptor agonist

A long-acting GLP-1 receptor agonist given once weekly by injection or daily by mouth. It is a licensed medicine for type 2 diabetes and for weight management.

Reconstitution calculator

At a glance

Licensed medicine

A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine: Semaglutide

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

3,032
papers on PubMed
1,556
of them in people
271
randomized trials
402
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Semaglutide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Semaglutide; no amount here is a recommendation.

Semaglutide: on PubMed

What PubMed held for Semaglutide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

3,032
papers
1,556
in humans
300
clinical trials
271
randomized trials
2012: 1 papers122013: 0 papers2014: 1 papers142015: 3 papers2016: 3 papers162017: 28 papers2018: 51 papers182019: 71 papers2020: 84 papers202021: 142 papers2022: 193 papers222023: 286 papers2024: 563 papers242025: 906 papers2026: 991 papers so far26
Papers per year, 2012 to 2026. The most in one year: 991.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis

    Meta-analysisTan HC, Dampil OA, Marquez MM Journal of the ASEAN Federation of Endocrine Societies, 2022. PMID 36578889

  2. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    Randomized trialWilding JPH, Batterham RL, Davies M, et al. Diabetes, obesity & metabolism, 2022. PMID 35441470

  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Randomized trialWilding JPH, Batterham RL, Calanna S, et al. The New England journal of medicine, 2021. PMID 33567185

  4. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    Randomized trialLincoff AM, Brown-Frandsen K, Colhoun HM, et al. The New England journal of medicine, 2023. PMID 37952131

  5. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

    TrialAronne LJ, Horn DB, le Roux CW, et al. The New England journal of medicine, 2025. PMID 40353578

  6. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

    Randomized trialRubino D, Abrahamsson N, Davies M, et al. JAMA, 2021. PMID 33755728

  7. Safety of Semaglutide

    ReviewSmits MM, Van Raalte DH Frontiers in endocrinology, 2021. PMID 34305810

  8. Semaglutide for the treatment of obesity

    ReviewChao AM, Tronieri JS, Amaro A, et al. Trends in cardiovascular medicine, 2023. PMID 34942372

Search used: ("Semaglutide"[ti]). Run it on PubMed

Research links

Also in Metabolic

Sold in blends: Cagrilintide + Semaglutide